Skip to main content

Table 2 Apabetalone suppresses the expression of inflammatory genes in unstimulated monocytes obtained from DM2 + CVD patients and control subjects

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

  1. aGene expression is expressed as mean fold difference in response to 25 μM apabetalone treatment relative to vehicle (DMSO). bGenes significantly downregulated in response to 5 μM apabetalone. cGenes differentially sensitive to apabetalone treatment in DM2 + CVD versus control cells (also shown in Fig. 3a). Italics numbers indicate a fold change of > 30% with an adjusted p value < 0.05 (two-way repeated measures ANOVA)